StockData
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc. (ALNY) stock

ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3048% below fair value
$143.82−4.00 (-2.71%)

Close on Nov 20, 2026Market cap $19.26BP/E 7.5Yield –

Alnylam Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Alnylam Pharmaceuticals's pe ratio was 28.1× on Nov 11, 2026, against 564.0× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202628.1×−468.9
2025Dec 31, 2025497.1×–

More Alnylam Pharmaceuticals figures

See a number that looks wrong?